• Pfizer's bid to take over U.K. pharmaceutical company AstraZeneca would have probably "fallen apart", Pascal Soriot, the firm's CEO, told CNBC.

  • Teva Pharma names Peterburg new chairman Wednesday, 26 Nov 2014 | 1:39 PM ET

    Nov 26- The board of Teva Pharmaceutical Industries Ltd elected Yitzhak Peterburg as its chairman, succeeding Phillip Frost, who is due to step down at the end of the year. The company also appointed Sol Barer, the former chief executive of Celgene Corp, as a director. Teva stock was up 0.8 percent at $57.02 on the New York Stock Exchange.

  • Bristol-Myers: FDA blocks hepatitis C drug for now Wednesday, 26 Nov 2014 | 1:37 PM ET

    U.S. regulators have declined to approve Bristol-Myers Squibb's daclatasvir as part of a combination hepatitis C treatment with another antiviral drug called asunaprevir. The FDA then requested more data on the effects of daclatasvir in combination with other drugs for treating hepatitis C, currently one of the hottest areas in drug research.

  • Bristol-Myers said it had initially sought permission from the U.S. Food and Drug Administration to market the drug, a so-called NS5A inhibitor, in combination with asunaprevir, one of the New York- based company's experimental medicines. But Bristol-Myers abandoned its U.S. marketing application for asunaprevir in October because of potential...

  • Pfizer to join forces with AstraZeneca?     Wednesday, 26 Nov 2014 | 4:35 AM ET

    American pharmaceutical giant has been pursuing AstraZeneca for some time, however CNBC's Catherine Boyle says it looks like the deal has "definitely receded".

  • Pfizer to renew pursuit of AstraZeneca?     Wednesday, 26 Nov 2014 | 1:20 AM ET

    Pfizer has seen off its six month cooling period before it can launch another bid for AstraZeneca, but will the American drugs giant continue its pursuit?

  • Searching for relief from expensive generic drugs Tuesday, 25 Nov 2014 | 2:24 PM ET
    Senator Amy Klobuchar

    Generic drug costs have risen so much that some drugs have surpassed their equivalents in other developed countries, the New York Times reports.

  • Merck, Iowa firm sign Ebola vaccine licensing deal Monday, 24 Nov 2014 | 1:28 PM ET

    TRENTON, N.J.ā€” Merck& Co., a top creator and seller of vaccines, has joined the fight against Ebola, the often-fatal hemorrhagic virus that's been ravaging parts of West Africa for months. The exclusive deal involves rVSV-EBOV, a vaccine candidate under early development by BioProtection Systems, the vaccine-development subsidiary of NewLink Genetics Corp. of...

  • Health care M&A leads global deal surge Sunday, 23 Nov 2014 | 9:01 AM ET

    "Health care has been a sleepy niche of M&A until recently, but the giant has been awakened," says Ken Menges, a senior partner handling M&A at law firm Akin Gump in New York. To a large extent, the deals are being driven by "cost pressure on the entire health care system," as insurers and government health plans increasingly hold down or even reduce reimbursements to drug,...

  • CNBC's Meg Tirrell, and Nancy Goodman, Kids v. Cancer founder, discuss the initiative to encourage drug companies to develop treatments for children with cancer and other rare diseases.

  • How to get cancer drugs to kids: A mother's take Friday, 21 Nov 2014 | 6:00 AM ET
    The Froman family, including Nancy Goodman, Mike Froman, and kids Ben and Sarah. They hold a photo of Jacob, who died of medulloblastoma, a rare form of brain cancer, at age 10.

    Kids facing cancer need access to promising ā€” albeit unapproved ā€” drugs, say these parents, who have faced the battle with their children firsthand.

  • Family gets $6.75 million in Botox treatment case Thursday, 20 Nov 2014 | 3:41 PM ET

    The verdict, in U.S. District Court in Burlington, came three days after the announcement that Parsippany, New Jersey- based drugmaker Actavis would acquire Botox maker Allergan for $66 billion, one of the biggest acquisitions announced this year. Thursday's verdict came four years after Irvine, California- based Allergan agreed to pay $600 million, pleading...

  • Sanofi: Wouldn't trade our pipeline     Thursday, 20 Nov 2014 | 1:47 PM ET

    Sanofi's global R&D President Dr. Elias Zerhouni, says he wouldn't trade his company's pipeline with anybody in the industry, and discusses the upcoming drug launches.

  • Nov 20- A U.S. court has denied a request by Indian drugmaker Ranbaxy Laboratories Ltd to stop competitors from launching copies of AstraZeneca Plc's heartburn pill Nexium and Roche's antiviral, a court filing showed. Ranbaxy had filed a lawsuit against the U.S. Food and Drug Administration last week for revoking tentative approvals it gave the company to make...

  • Soaring generic drug prices draw Senate scrutiny Thursday, 20 Nov 2014 | 8:32 AM ET

    WASHINGTONā€” Some low-cost generic drugs that have helped restrain health care costs for decades are seeing unexpected price spikes of up to 8,000 percent, prompting a backlash from patients, pharmacists and now Washington lawmakers. Members of the Senate meet Thursday to scrutinize the recent, unexpected trend among generic medicines, which are copies of...

  • Nov 20- A U.S. court has denied a request by Indian drugmaker Ranbaxy Laboratories Ltd to stop competitors from launching copies of AstraZeneca Plc's heartburn pill Nexium and Roche's antiviral Valcyte, a court filing showed. Ranbaxy had sought the restraining order against Dr Reddy's Laboratories and U.S. firm Endo International Plc in a lawsuit it filed...

  • Nov 20- Global pharmaceutical spending will break the trillion dollar mark in 2014, driven by high prices in the United States for novel treatments such as Gilead Sciences Inc's Sovaldi for hepatitis C and new cancer drugs, according to a study released on Thursday. Total spending on drugs will hit $1.06 trillion, an increase of 7 percent over 2013 levels,...

  • Nov 18- The estimated average cost of developing an approved new drug has more than doubled to more than $2.5 billion from a 2003 estimate by Tufts University, but critics questioned the figure and noted the school's strong financial ties to the pharmaceutical industry. The Tufts Center for the Study of Drug Development, located in Boston, in 2003 estimated the...

  • AstraZeneca trumpets strength in drug development Tuesday, 18 Nov 2014 | 3:24 AM ET
    British pharmaceutical company AstraZeneca's manufacturing site in Macclesfield, northwest England.

    AstraZeneca said it had made good progress in developing a pipeline of new drugs.

  • Outbreaks like Ebola will happen again: NIH Monday, 17 Nov 2014 | 3:57 PM ET
    File photo: A young man, dressed in a biohazard costume, stands on the corner of 546 West 147th Street in October 2014 in New York City after an American doctor carrying the ebola virus was admitted to Bellevue Hospital

    NIH's Dr. Francis Collins and Milken Institute Chairman Mike Milken make the case for medical research funding to stop outbreaks like Ebola.